Release Summary

Merck's Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Study

Merck & Co., Inc.